PE20130014A1 - Hidrato del hidrobromuro de agomelatina y preparacion de este - Google Patents

Hidrato del hidrobromuro de agomelatina y preparacion de este

Info

Publication number
PE20130014A1
PE20130014A1 PE2012001449A PE2012001449A PE20130014A1 PE 20130014 A1 PE20130014 A1 PE 20130014A1 PE 2012001449 A PE2012001449 A PE 2012001449A PE 2012001449 A PE2012001449 A PE 2012001449A PE 20130014 A1 PE20130014 A1 PE 20130014A1
Authority
PE
Peru
Prior art keywords
agomelatin
hydrobromide hydrate
preparation
disorders
refers
Prior art date
Application number
PE2012001449A
Other languages
English (en)
Inventor
Hanbin Shan
Xueyan Zhu
Hongjuan Pan
Zhedong Yuan
Peng Zhang
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44599557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20130014A1 publication Critical patent/PE20130014A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN HIDRATO DEL HIDROBROMURO DE AGOMELATINA DE FORMULA (I) DONDE X ES BROMO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL HIDRATO DE HIDROBROMURO DE AGOMELATINA QUE COMPRENDE A) DISOLVER LA AGOMELATINA EN UN DISOLVENTE ORGANICO TAL COMO ACETATO DE ETILO; B) ANADIR UNA DISOLUCION ACUOSA DE HBr GOTA A GOTA PARA PRECIPITAR EL CRISTAL DEL PRODUCTO SIENDO LA TEMPERATURA DE REACCION DE 0ºC A 20ºC; C) LAVAR Y SECAR EL SOLIDO DESPUES DE LA CRISTALIZACION. DICHO HIDRATO DE HIDROBROMURO DE AGOMELATINA ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS DEL SISTEMA MELATONINERGICO, TRANSTORNOS DEL SUENO, ANSIEDAD, TRANSTORNOS DEPRESIVOS, ESQUIZOFRENIA
PE2012001449A 2010-03-17 2011-03-17 Hidrato del hidrobromuro de agomelatina y preparacion de este PE20130014A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101262639A CN102190595A (zh) 2010-03-17 2010-03-17 阿戈美拉汀溴化氢水合物及其制备方法

Publications (1)

Publication Number Publication Date
PE20130014A1 true PE20130014A1 (es) 2013-01-26

Family

ID=44599557

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001449A PE20130014A1 (es) 2010-03-17 2011-03-17 Hidrato del hidrobromuro de agomelatina y preparacion de este

Country Status (39)

Country Link
US (1) US8729132B2 (es)
EP (1) EP2547650B1 (es)
JP (1) JP5634533B2 (es)
KR (1) KR101406736B1 (es)
CN (2) CN102190595A (es)
AP (1) AP3199A (es)
AU (1) AU2011229619B2 (es)
BR (1) BR112012023173B1 (es)
CA (1) CA2792430C (es)
CL (1) CL2012002541A1 (es)
CR (1) CR20120461A (es)
CU (1) CU20120136A7 (es)
CY (1) CY1117134T1 (es)
DK (1) DK2547650T3 (es)
EA (1) EA022066B1 (es)
EC (1) ECSP12012156A (es)
ES (1) ES2572427T3 (es)
GE (1) GEP20156232B (es)
GT (1) GT201200260A (es)
HK (1) HK1177732A1 (es)
HN (1) HN2012001923A (es)
HR (1) HRP20151343T1 (es)
HU (1) HUE026673T2 (es)
IL (1) IL221783A (es)
MA (1) MA34054B1 (es)
ME (1) ME02309B (es)
MX (1) MX2012010594A (es)
MY (1) MY160337A (es)
NI (1) NI201200141A (es)
NZ (1) NZ602451A (es)
PE (1) PE20130014A1 (es)
PL (1) PL2547650T3 (es)
PT (1) PT2547650E (es)
RS (1) RS54449B1 (es)
SG (1) SG183869A1 (es)
SI (1) SI2547650T1 (es)
TN (1) TN2012000436A1 (es)
UA (1) UA105424C2 (es)
WO (1) WO2011113363A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2851363B1 (en) * 2012-05-14 2018-01-03 Shanghai Righthand Pharmtech. Co., Ltd. Agomelatine acid radical composite, and preparation method and application thereof
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PL366150A1 (en) * 2000-10-30 2005-01-24 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用

Also Published As

Publication number Publication date
US8729132B2 (en) 2014-05-20
CN102892749B (zh) 2014-11-05
US20130012592A1 (en) 2013-01-10
TN2012000436A1 (en) 2014-01-30
MA34054B1 (fr) 2013-03-05
UA105424C2 (uk) 2014-05-12
GT201200260A (es) 2013-11-18
RS54449B1 (en) 2016-06-30
EP2547650A4 (en) 2013-09-18
ECSP12012156A (es) 2012-12-28
MY160337A (en) 2017-02-28
AP3199A (en) 2015-03-31
KR101406736B1 (ko) 2014-06-12
PL2547650T3 (pl) 2016-06-30
MX2012010594A (es) 2012-10-03
KR20120128713A (ko) 2012-11-27
CU20120136A7 (es) 2012-12-17
HN2012001923A (es) 2015-09-14
CY1117134T1 (el) 2017-04-05
EA201201293A1 (ru) 2013-04-30
CN102892749A (zh) 2013-01-23
SI2547650T1 (sl) 2016-02-29
HUE026673T2 (en) 2016-07-28
JP5634533B2 (ja) 2014-12-03
CA2792430A1 (en) 2011-09-22
BR112012023173A2 (pt) 2016-05-17
AU2011229619A1 (en) 2012-09-27
ME02309B (me) 2016-06-20
CA2792430C (en) 2015-12-08
NI201200141A (es) 2012-11-09
AU2011229619B2 (en) 2014-05-22
DK2547650T3 (en) 2016-02-15
EP2547650B1 (en) 2015-11-04
HRP20151343T1 (hr) 2016-01-01
HK1177732A1 (en) 2013-08-30
NZ602451A (en) 2014-10-31
IL221783A (en) 2017-11-30
GEP20156232B (en) 2015-01-26
ES2572427T3 (es) 2016-05-31
CN102190595A (zh) 2011-09-21
JP2013522242A (ja) 2013-06-13
SG183869A1 (en) 2012-10-30
CL2012002541A1 (es) 2013-01-11
PT2547650E (pt) 2015-11-30
EA022066B1 (ru) 2015-10-30
WO2011113363A1 (en) 2011-09-22
EP2547650A1 (en) 2013-01-23
CR20120461A (es) 2012-11-29
AP2012006493A0 (en) 2012-10-31
BR112012023173B1 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
PE20130013A1 (es) Hidrato del hidrocloruro de agomelatina y preparacion de este
AR098110A1 (es) Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
UY33249A (es) Proceso para la preparacion de derivados de isoxazolina
JP2011126894A5 (es)
UY35156A (es) Derivados del ácido indaniloxi dihidrobenzofuranil acético como agonistas de las gpr40
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
CU24499B1 (es) Proceso para preparar ésteres de ácido láctico y ácido 2-hidroxi-3-butenoico a partir de azúcares
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112014018376A8 (pt) Método de purificação de silício
PE20130014A1 (es) Hidrato del hidrobromuro de agomelatina y preparacion de este
MY164790A (en) Purification of bio-based acrylic acid to crude and glacial acrylic acid
AR075915A1 (es) Proceso para la obtencion de derivados de acido propionico
AR107494A1 (es) Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma
BR112013021671A2 (pt) processo para a preparação de um campo de poliéster hiper-ramificado da invenção
ES2571043T3 (es) Preparación de dihidropiridinas
BR112015007492A2 (pt) pré-mistura estabilizadora de enzima estável
AR081267A1 (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
BR112014009266A8 (pt) processos encurtado, biocatalítico e para preparação de ácidos isoxazolil-metóxi-nicotínicos
PE20121741A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
MX2017006298A (es) Proceso para producir acido acetico introduciendo un compuesto de litio.
AR094240A1 (es) Proceso para producir cristal de compuesto de pirazol
BR112013026747A2 (pt) processo e aparelho
BR112013023933A2 (pt) recuperação de energia do licor-mãe no processo de cristalização de paraxileno
CO6741224A2 (es) Formas cristalinas de un ácido alcoxiimidazol-1-ilmetil bifenil carboxílico
NI201400017A (es) 2 - (croman - 6 - iloxi ) - tiazoles sustituidos y su uso como productos farmacéuticos

Legal Events

Date Code Title Description
FG Grant, registration